A possibility of MAPK signaling as a target of combination therapy with HDAC inhibitor
| Project/Area Number |
16K19732
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
IBUSUKI Atsuko 鹿児島大学, 医歯学域医学系, 助教 (10596109)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 皮膚リンパ腫 / HDAC阻害剤 / MAPK / キナーゼ活性 |
|---|
| Outline of Final Research Achievements |
I performed the exhaustive protein tyrosine kinase assay of 3 CTCL cell lines (Hut78, HH and MJ) with 3 HDACi (romidepsin, vorinostat and belinostat) by Pamchip and found that all tested HDACi upregulated phosphorylation activity of MAPK1/ERK2 in Hut78. Furthermore, inhibitors of MEK, an upstream kinase of MAPK1, significantly enhanced the anti-proliferative effect of HDACi in Hut78.
|
Report
(3 results)
Research Products
(10 results)
